12/31/2010 | CVLM | Antigenics to exchange shares for $8.05 million of 5.25% convertibles
|
12/13/2010 | CVLM | Antigenics plans to buy back convertibles from majority holder Ingalls
|
4/22/2010 | CVLM | Antigenics issues shares for $2.29 million 5.25% convertibles, amends terms of 2006 convertibles
|
9/11/2009 | CV | Antigenics exchanges shares for $1.27 million 5.25% convertibles
|
6/9/2009 | CV | Antigenics to swap shares for $2 million 5.25% convertibles due 2025
|
6/5/2009 | CV | Antigenics to exchange $1.5 million 5.25% convertibles for shares
|
6/4/2009 | CV | Antigenics agrees to issue stock for $12.4 million 5.25% convertibles
|
6/3/2009 | CV | Market Commentary: Convertibles quiet as players eye JetBlue, Biovail, Steel Dynamics; Cephalon, Human Genome up
|
2/19/2009 | CV | Antigenics buys back $11.8 million in convertibles
|
11/14/2008 | CV | Antigenics amends 2006 notes to allow repurchase of 5.25% convertibles
|
5/29/2008 | CVHY | Antigenics files $100 million shelf registration
|
4/17/2007 | CV | Market Commentary: Antigenics eases after surge; BioMarin, Lawson gain in gray; Linear, Delta Petroleum launch deals
|
4/16/2007 | CV | Market Commentary: Antigenics climbs on drug data; Electronic Data flat as rumors continue; BioMarin, Lawson launch deals
|
2/21/2007 | CVSS | Antigenics ends 2006 with $40 million, reduces cash burn while growing pipeline
|
1/24/2005 | CV | Market Commentary: Rite Aid launches deal for Tuesday; Tower Auto bids bounce; Brocade news apt to boost bonds
|
1/21/2005 | CV | Market Commentary: Fortis/Assurant settles at 102.5; Celanese ends around par; Tower Automotive bonds in a freefall
|
1/20/2005 | CV | New Issue: Antigenics sells downsized $50 million convertible at 5.25%, up 20%
|
1/20/2005 | CV | Market Commentary: Celanese seen getting upsized; Fortis/Assurant issue bid well; Alexion, Antigenics trip out of chute
|
1/19/2005 | CV | Market Commentary: Alexion goes to 102; Antigenics sweetens terms; Charter exodus continues; auto, airline paper lower
|
1/18/2005 | CV | Antigenics $60 million convertible talked to yield 4.75%-5.25%, up 35%-40%
|
1/18/2005 | CV | Market Commentary: Antigenics, Alexion deals emerge; Charter slides on CEO's exit; Computer Network gains
|
11/27/2001 | CVHY | Antigenics files $100 million debt, preferred, stock, convertibles shelf
|